• For the treatment of postmenopausal vaginal atrophy symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
• Blissel^Ⓡ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
• Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.
• Before estriol treatment is initiated or reinstituted, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contraindications and warnings for use.

Please refer to the Summary of Product Characteristics before prescribing.¹

1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Common (≥1/100 to <1/10) and (≥1/1000 to <1/100) undesirable effects¹

Date of preparation: April 2026 Item code: UK-BLS-671(1)